BeOne Medicines (NASDAQ:ONC) Insider Lai Wang Sells 1,068 Shares of Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) insider Lai Wang sold 1,068 shares of the company’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $276.74, for a total transaction of $295,558.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Lai Wang also recently made the following trade(s):

• On Tuesday, June 16th, Lai Wang sold 1,169 shares of BeOne Medicines stock. The shares were sold at an average price of $265.39, for a total transaction of $310,240.91.
• On Thursday, June 11th, Lai Wang sold 756 shares of BeOne Medicines stock. The shares were sold at an average price of $261.00, for a total transaction of $197,316.00.
• On Monday, June 8th, Lai Wang sold 1,367 shares of BeOne Medicines stock. The shares were sold at an average price of $269.38, for a total transaction of $368,242.46.

BeOne Medicines Stock Performance

Shares of ONC stock opened at $275.34 on Friday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. The firm has a market cap of $30.21 billion, a P/E ratio of 61.60 and a beta of 0.49. The firm’s 50 day moving average price is $292.55 and its 200-day moving average price is $310.42. BeOne Medicines Ltd. – Sponsored ADR has a one year low of $239.25 and a one year high of $385.22.

BeOne Medicines (NASDAQ:ONC) last posted its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. The firm had revenue of $1.51 billion during the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. As a group, equities research analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets raised its position in shares of BeOne Medicines by 100.6% during the 4th quarter. BNP Paribas Financial Markets now owns 193,951 shares of the company’s stock worth $58,924,000 after acquiring an additional 97,244 shares in the last quarter. Slow Capital Inc. increased its stake in BeOne Medicines by 51.5% in the fourth quarter. Slow Capital Inc. now owns 27,301 shares of the company’s stock valued at $8,294,000 after purchasing an additional 9,280 shares during the last quarter. Generali Investments Management Co LLC purchased a new position in BeOne Medicines in the third quarter valued at approximately $2,726,000. Capital International Sarl raised its holdings in BeOne Medicines by 2.7% during the fourth quarter. Capital International Sarl now owns 152,515 shares of the company’s stock worth $46,336,000 after purchasing an additional 3,956 shares in the last quarter. Finally, AIA Group Ltd lifted its position in shares of BeOne Medicines by 31.4% during the 3rd quarter. AIA Group Ltd now owns 32,303 shares of the company’s stock worth $11,006,000 after buying an additional 7,716 shares during the last quarter. Hedge funds and other institutional investors own 48.55% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ONC. Jefferies Financial Group lowered BeOne Medicines from a “buy” rating to a “hold” rating and decreased their target price for the stock from $420.00 to $290.00 in a research note on Monday, March 16th. Barclays increased their price target on shares of BeOne Medicines from $405.00 to $409.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Wall Street Zen cut shares of BeOne Medicines from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 20th. Zacks Research raised shares of BeOne Medicines from a “hold” rating to a “strong-buy” rating in a research note on Thursday, June 4th. Finally, Wells Fargo & Company assumed coverage on shares of BeOne Medicines in a report on Monday, May 4th. They set an “overweight” rating and a $400.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, BeOne Medicines has an average rating of “Moderate Buy” and an average price target of $390.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.